

I. Identification


Chemical name : 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione,polymer and copolymer thereof.

Chemical family : Polyester

Common names : Polylactide, polylactic acid, PLA; Polyglycolide, Polyglycolic acid, PGA; Poly(lactide-co-glycolide), PLG .

Chemical formula : $(C_6H_8O_4)_x$, $(C_4H_4O_4)_y$, $(C_6H_8O_4)_x(C_4H_4O_4)_y$.

Chemical structure :



II. Components

<u>Material</u>	<u>CAS#</u>	<u>Hazard</u>
L-lactide	4511-42-6	None known
DL-Lactide	615-95-2	None known
Glycolide	502-97-6	None known
Poly(DL-lactide)	26680-10-4	None known
Poly(L-lactide)	33135-50-1	None known
Poly(glycolide)	26202-08-4	None known
Poly(L-lactide-co-glycolide)	30846-39-0	None known
Poly(DL-lactide-co-glycolide)	26780-50-7	None known
Poly(L-lactide-co-DL-glycolide)	52305-30-3	None known

- ☐ Home
- ☐ About Us
- ☐ Subscribe
- ☐ Media Planner
- ☐ Current Issue
 - Market News
 - Library
 - Product Showcase
 - Advertisers
- ☐ Company Showcase
- ☐ Event Calendar
- ☐ Back Issues
- ☐ Submission Guidelines
- ☐ Contact Us
- ☐ Industry Links

NOW OPEN

[Click Here](#)

PLGA-PEG COPOLYMERS

Articles: PLGA-PEG Block Copolymers for Drug Formulations

By: Kang Moo Huh, PhD; Yong Woo Cho, PhD; and Kinam Park, PhD

ABSTRACT

Over the past few decades, biodegradable polyesters, such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactic-co-glycolic acid) (PLGA), have been extensively studied for a wide variety of pharmaceutical and biomedical applications. The biodegradable polyester family has been regarded as one of the few synthetic biodegradable polymers with controllable biodegradability, excellent biocompatibility, and high safety. The need for a variety of drug formulations for different drugs and degradation pathways resulted in development of various types of block copolymers (eg, diblock, triblock, multiblock, and star-shaped block) consisting of the biodegradable polyester and poly(ethylene glycol) (PEG). Extensive studies throughout the world have produced encouraging results demonstrating many desirable, unique properties of PLGA-PEG block copolymers. Despite successes in preclinical applications and ever-increasing use in diverse research activities, PLGA-PEG block copolymers are currently not available commercially. Recognizing that demands for PLGA-PEG block copolymers in pharmaceutical and biomedical applications will continue to grow, Akina, Inc., (www.akinainc.com/polycelle) has started production of PLGA-PEG block copolymers for those who want to use the block copolymers but are not willing to synthesize them. This article describes synthesis of PLGA-PEG block copolymers and their application in drug delivery vehicles, such as micro/nano-particles, micelles, hydrogels, and injectable delivery systems.

INTRODUCTION


Recently, biodegradable polymers, especially poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactic-co-glycolic acid) (PLGA), have been used significantly in pharmaceutical and biomedical applications. Poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) have also been called polylactide, polyglycolide, and (lactide-co-glycolide), respectively, according to the nomenclature system based on the source of the polymer. Although these names were used in many references in the past, a recent trend is to follow the nomenclature system of the International Union of Pure and Applied Chemistry (IUPAC) that is based on the repeating unit structure. PLA, PGA, and PLGA can be degraded into non-toxic substances and removed from the human body. Accordingly, they have taken center stages in a variety of research efforts.

The biodegradable polyesters are all strongly hydrophobic, and this has caused several limitations in practical drug formulations. To add hydrophilic and other physicochemical properties, poly(ethylene glycol) (PEG) has been incorporated into the biodegradable polyesters. PEG is a non-toxic, water-soluble polymer with proven biocompatibility. Block copolymers consisting of a hydrophobic polyester segment and a hydrophilic PEG segment have attracted large attention due to their biodegradability, biocompatibility, and tailor-made properties. A wide variety of drug formulations, such as micro/nano-particles,

micelles,² hydrogels,³ and injectable drug delivery systems⁴ have been developed using PLGA-PEG block copolymers. They have been extensively investigated for use in a range of applications, including implantable materials, drug delivery systems, and engineering scaffolds. They are very useful materials for pharmaceutical and biomedical applications, and thus they have significant commercial potential. Demands for these copolymers will continue to grow, and they are expected to build a great market for their precursors, such as PLA, PGA, and PLGA, did. This review includes synthetic materials, PLGA-PEG block copolymers and their applications in controlled drug delivery. In addition, availability and significance of commercial production of the block copolymers are briefly described.

FIGURE 1

Chemical structure of poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(lactic-co-glycolic acid) (PLGA).



PLA, PGA & PLGA AS BIOMATERIALS

Biodegradable polymers have been extensively used in controlled drug delivery. They have the advantage of not requiring surgical removal after they serve their intended purposes. PGA, PLA, and especially their copolymers PLGA are the most commonly used family of biodegradable polymers. PGA was used as a biodegradable suture material in the 1970s, and it has led the largest volume production in the biomedical polymer markets, when its production was combined with those of PLA and PLGA; then, they have found a broad range of pharmaceutical and biomedical applications based on their unique properties, including versatile degradation kinetics, non-toxicity, and biocompatibility.⁶ The general properties and typical applications of PGA, PLA, and PLGA are summarized in Table 1.

Table 1. Properties and applications of PGA, PLA, and PLGA^{1,2}

Polymer	Crystallinity	T _g (°C)	Degradation Rate ^a	Typical applications
PGA	Highly crystalline (T _m =225~230°C)	35 ~ 40	2-3 months	Suture, Soft anaplerosis
PLA (L form)	Semicrystalline (T _m =173~178°C)	60 ~ 65	> 2 years	Fracture fixation, Ligament augmentation
PLA (D, L form)	Amorphous	55 ~ 60	12-16 months	Drug delivery system
PLGA	Amorphous	45 ~ 55	1-6 months ^b	Suture, Fracture fixation, Ora implant, Drug delivery microsphere

a. Rate depends on molecular weights of the polymers.


b. Rate may change according to the ratio of LA and GA.

PGA is a highly crystalline polymer and the most hydrophilic among them. It has a high melting point (224°C to 226°C), and the degradation rate of PGA is much higher than that of PLA. Random PLGA copolymers with different ratios of lactide (LA) and glycolide (GA) exhibit different degradation rates, and thus can be tailor-made for applications requiring specific degradation kinetics ranging from weeks to months. They are generally more amorphous than their homo-polymers and become most susceptible to hydrolysis when the two monomer contents are the same.


SYNTHESIS OF PLGA-PEG BLOCK COPOLYMERS

One useful strategy for modifying the physicochemical and biological properties of hydrophobic and biodegradable PLA, PGA, and PLGA has been to incorporate hydrophilic PEG segments. It is known that low molecular weight PEGs are easily excreted in humans. Many synthetic methods were developed to prepare various block copolymers with different block structures and compositions.

The biodegradation rate and hydrophilicity of block copolymers can be modulated by adjusting the ratio of its hydrophilic and hydrophobic constituents. Usually, PLGA block copolymers have shown quite different properties when compared to each constituting polymer. For this reason, PLGA-PEG block copolymers became a new class of biomaterials with their own unique properties, such as microphase separation, crystallinity, water-solubility, and biodegradability. Various kinds of block copolymers have been developed to date and can be classified according to their block structure: AB diblock,⁷ ABA,^{1,8} or BAB^{4,9} triblock, multi-block,^{10,11} branched block,¹² star-shaped block,¹³ and graft block¹⁴ copolymers, in which A is a hydrophobic block made up of biodegradable polyesters and B is a hydrophilic PEG block, as shown in Figure 2.



Homo- and copolymers of LA and GA are usually synthesized by ring-opening polymerization of cyclic monomers. The block copolymers can be synthesized using various kinds of different catalysts, but also in the absence of catalysts. One of the widely used catalysts is stannous octoate. Figure 3 shows a typical example for the synthesis of PLGA-PEG block copolymers using stannous octoate. The terminal hydroxyl groups of PEG have been used as the initiating groups to synthesize block copolymers. The ring opening polymerization of lactide and glycolide initiated by dihydroxy PEG or monomethoxy PEG can lead to A-B-A or A-B type block copolymers, respectively. Alternating multiblock copolymers of PLA and PEG can be obtained by coupling the diblock copolymers using hexamethylene diisocyanate. Alternating multiblock copolymers of PLA and PEG can be synthesized by polycondensation reaction between dihydroxy PEG and dicarboxylic acid. ¹⁰ Dicarboxylated oligomeric PLAs were synthesized as macro-monomers by the condensation reaction of lactic acid in the presence of succinic acid. Kissel et al. synthesized star-shaped block copolymers from multi-arm PEG and lactide or lactide/glycolide. Biodegradable star-shaped PLA-PEG and PLGA-PEG block copolymers can be synthesized by ring opening polymerization in the presence of 4- or 8-branched PEG using aluminum triethylene as a catalyst.



PROPERTIES OF PLGA-PEG BLOCK COPOLYMERS

One typical characteristic of PLGA degradation is autocatalysis by which heterog bulk degradation is observed with a decrease in pH. Carboxylic end groups of de products, oligomeric PLGA, can accelerate the degradation and decrease the loc PLGA formulations. This locally acidified environment is known to be a main reas protein inactivation and often requires incorporation of antacids, such as $\text{Mg}(\text{OH})$ the polymers for protein stabilization by neutralization.¹⁶ In addition, other limitati such as hydrophobicity, brittleness, and toxicity, have been reported with PLGA formulations. Block copolymers containing hydrophilic PEG segments have attrac considerable attention as an alternative approach for overcoming such undesirab effects and improving the properties in applications of PLGA as drug delivery veh Through various synthetic processes, diverse block copolymers with a wide rang molecular weights, chemical structure, and hydrophilic/hydrophobic block ratios h been prepared and used in controlled drug delivery.

The chemical composition and molecular weight of block copolymers determines water-solubility and degradation kinetics. Polymers with low molecular weight or composed of shorter hydrophobic blocks are soluble in water, whereas high mole weight polymers and polymers with longer hydrophobic blocks are not soluble bu water. In general, the degradation time will be shorter for low molecular weight pc more hydrophilic polymers, more amorphous polymers, and copolymers with high content of glycolide. Therefore, at identical conditions, low molecular weight copc of lactide and glycolide will degrade relatively rapidly, whereas the high molecula homopolymers, PLA, and PGA will degrade much more slowly.


PLGA-PEG BLOCK COPOLYMERS IN DRUG FORMULATIONS

Various types of drug formulations, such as nano/micro-particles, hydrogels, micr and injectable delivery systems have been developed using PLGA-PEG block copolymers to deliver hydrophobic drugs as well as hydrophilic peptide and prote The ability of the polymers to entrap drugs and subsequently release them at a c rate has been used to develop various drug formulations.

Nano/Microparticles

ABA triblock copolymers are more hydrophilic than PLA or PLGA itself, and are considered more suitable for development of delivery systems for hydrophilic


macromolecular drugs, such as peptides, proteins, and oligo/polynucleotides. Micro-nano-particles prepared from AB diblock and ABA triblock copolymers are extensively investigated for protein drug delivery.^{1,17-19} Block copolymer nano/microparticles are generally prepared by water/oil/water (W/O/W) double emulsion method, as shown in Figure 4. The W1 phase, an aqueous phase containing protein drugs, is dispersed into the oil phase consisting of polymer dissolved in organic solvent (eg, dichloromethane) using a high-speed homogenizer. The primary water-in-oil (W/O) emulsion is then dispersed into an aqueous solution containing a polymeric surfactant, eg, poly(vinyl alcohol) (PVA), and further homogenized to produce a W/O/W emulsion. After several hours, the nano/microparticles are collected by filtration. They show quite different release patterns when compared with PLGA. Kissel et al. reported that ABA triblock copolymers showed a continuous and molecular mass-dependent release, while the release from PLGA was biphasic and almost independent of the molecular mass of the entrapped substances.⁸



Polymeric Micelles

Amphiphilic PLGA-PEG block copolymers form micelles composed of a hydrophobic

PLGA core and hydrophilic PEG shell in water, as shown in Figure 5. Hydrophobic segments are segregated from the aqueous exterior to form an inner core surrounded by a shell of hydrophilic segments. Block copolymer micelles are water-soluble, biocompatible nanocontainers in the size of 10~100 nm with proven efficacy of delivering hydrophobic drugs. These micelle-forming block copolymers can provide high concentration of hydrophobic drugs with increased drug stability in an aqueous milieu above the solubility limit of the drug. The ability of polymeric micelles to target certain cells (eg, cancer cells) can also lower the required dosage.²⁰ The size and morphology of block copolymer micelles can be easily changed by adjusting the chemical composition, total molecular weight, and ratio of the block lengths. Various hydrophobic drugs, including paclitaxel, have been incorporated into the hydrophobic inner core of micelles.




Hydrogels

When the block copolymers have high molecular weights and high PLGA content, they become water-insoluble but can swell in water. Block copolymers consisting of hydrophilic and hydrophobic blocks are able to form physical crosslinking in an aqueous environment through hydrophobic interaction, crystalline microdomains or chain entanglement.³ Physical associations of hydrophobic domains maintain swollen states, keeping the polymer network stable in water. Although physical associations are reversible and weaker than chemical crosslinking, they allow sol casting and thermal processing, and the resulting polymer gels often possess elastoviscoelastic properties. These biodegradable, physical hydrogels may offer an alternative material of choice in designing drug delivery systems as well as other biomedical applications.¹¹

Injectable Drug Delivery Systems

Aqueous solutions of low molecular weight B-A-B type triblock copolymers are well known to have thermo-reversible sol-gel transitions, forming in situ hydrogels without the use of harmful organic solvents or any chemical reactions.^{4,9,21} Figure 6 schematically represents the thermo-reversible sol-gel transition of the triblock copolymers. They can be loaded with drugs in aqueous phase at low temperature (below critical gelation temperature) where they form a sol. Just following subcutaneous injection, the elevated temperature to 37°C (above critical gelation temperature) makes the injected sol transition into a gel that can act as a sustained-release matrix for the loaded drugs. Thermo-reversible hydrogels have recently attracted large attention due to the simplicity of drug formulation by solution mixing, biocompatibility with biological systems, and convenient administration. Pharmaceutical and biomedical applications of the block copolymers include solubilization of low molecular weight hydrophobic drugs, controlled release of labile biomacromolecules (eg, proteins and genes), cell immobilization, and tissue engineering.



LACK OF COMMERCIAL SOURCES FOR PLGA-PEG BLOCK COPOLYMERS

Biodegradable polymers have been playing a key role in various pharmaceutical biomedical research and product development. Materials that can degrade and dissolve from the body are desirable for a number of applications, including orthopedics, tissue engineering, and controlled drug delivery systems. For this reason, a number of commercial sources supply PLA, PGA, and PLGA throughout the world. However, there are no commercial sources supplying block copolymers consisting of hydrophobic blocks of PLA, PGA, or PLGA and hydrophilic PEG blocks. These block copolymers have properties that homopolymers cannot provide, and are ideal for formulating controlled drug delivery systems and for making scaffolds for tissue engineering. Yet their commercial introduction has not been made to date. Demands for these block copolymers are expected to grow as the pharmaceutical and biomedical fields continue to grow.

COMMERCIAL PRODUCTION OF PLGA-PEG COPOLYMERS

During the past few decades, significant advances have been made in polymeric drug delivery technology. Drug delivery in the future will need more sophisticated and complex formulations for existing drugs as well as new drugs, such as protein and peptide drugs. Biodegradable polymers have an important role in the development of controlled drug formulations. PLGA-PEG block copolymers have a number of unique and useful properties that are ideal for controlled drug delivery. The properties of sol-gel transition at well-defined temperatures and biodegradability make block copolymers an ideal drug delivery vehicle for various drugs, including protein drugs. Numerous new protein drugs are expected in the near future as a result of an increased understanding of genomics and proteomics. Thus, demands for the PLGA-PEG block copolymers are expected to grow exponentially for both research and product development in the coming years. To meet the current needs and prepare for the future demands, Akina, Inc., started producing biodegradable PLGA-PEG block copolymers for those who wish to use them in their research and development of drug delivery systems (www.akinainc.com/polycell).

Synthetic methods for the block copolymers are well established, and Akina produces block copolymers consisting of glycolide, lactide, and PEG. These three main building blocks can be assembled into a wide variety of different combinations to synthesize block copolymers with diverse, but tailor-made, properties. Properties, such as degradation rate, hydrophilicity, crystallinity, and solubility, can be easily custom-made for specific applications.

REFERENCES


1. Morlock M, Kissel T, Li YX, Koll H, Winter G. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release pro Control Rel. 1998;56:105-115.
2. Liggins RT, Burt HM. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formations. Adv Drug Delivery Rev. 2002;54:191-202.
3. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Delivery Rev. 2002;43:1-12.
4. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery s Nature. 1997;388:860-862.
5. Ikada Y, Tsuji H. Biodegradable polyesters for medical and ecological applications. Macromol Rap Commun. 2000;21:117-132.
6. Chaubal M. Polylactides/glycolides-exipients for injectable drug delivery and beyond. Drug Deliv Technology. 2002;2:34-36.
7. Beletsi A, Leontiadis L, Klepetsanis P, Ithakissios DS, Avgoustakis K. Effect of preparative variable properties of poly(dl-lactide-co-glycolide)-methoxypoly(ethyleneglycol) copolymers related to their in controlled drug delivery. Int J Pharm. 1999;182:187-197.
8. Kissel T, Li Y, Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydroxy (ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Delivery Rev. 2002;54:99-134.
9. Jeong B, Bae YH, Kim SW. Drug release from biodegradable injectable thermosensitive hydrogel of PLGA-PEG triblock copolymers. J. Control Rel. 2000;63:155-163.
10. Huh KM, Bae YH. Synthesis and characterization of poly(ethylene glycol)/poly(l-lactic acid) alternating multiblock copolymers. Polymer. 1999;40:6147-6155.
11. Bae YH, Huh KM, Kim Y, Park KH. Biodegradable amphiphilic multiblock copolymers and their importance for biomedical applications. J Control Rel. 2000;64:3-13.
12. Hrkach JS, Peracchia MT, Domb A, Lotan N, Robert L. Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy. Biomaterials. 1997;18:27-30.
13. Breitenbach A, Li YX, Kissel T. Branched biodegradable polyesters for parenteral drug delivery systems. Control Rel. 2000;64:167-178.
14. Jeong B, Kibbey MR, Birnbaum JC, Won YY, Gutowska A. Thermogelling biodegradable polymers with hydrophilic backbones: PEG-g-PLGA. Macromolecules. 2000;33:8317-8322.
15. Li Y, Kissel T. Synthesis, characteristics and in vitro degradation of star-block copolymers consisting of lactide, glycolide, and branched multi-arm poly(ethylene oxide). Polymer. 1998;39:4421-4427.
16. Zhu G, Mallory SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly(lactide-glycolide). Nature Biotechnol. 2000;18:52-56.
17. Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuan WF, Zhou JJ, Zhu JH, Gao XJ. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Rel. 2003;203:203-211.
18. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller RH. Stealth nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. J Biomater Sci Polym Ed. 2000;12:301-313.
19. Choi Y, Kim SY, Kim SH, Lee KS, Kim C, Byun Y. Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG/PLLA blended microspheres. Int J Pharm. 2001;215:67-81.
20. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300:615-618.
21. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Delivery Rev. 2002;54:37-51.
22. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as medical devices. Medical Plastics & Biomaterials. 1998;5(2):30-39.

BIOGRAPHIES



Dr. Kang Moo Huh is a Principal Scientist at Akina, Inc., where he is engaged in research projects related to the development of biodegradable block copolymers superporous hydrogels for drug delivery and tissue engineering applications. Dr.

earned his BS in Polymer Science and Engineering from Chungnam National University (South Korea), his MS in Materials Science and Engineering from Kwangju Institute of Science and Technology (South Korea), and his PhD in the School of Materials Science from Japan Advanced Institute of Science and Technology (Japan). He completed Post-doctoral research at the Biomedical Center of Korea Institute of Science and Technology, where he participated in the development of polymeric gene carriers and injectable hydrogels. Research interests include design and synthesis of stimuli-responsive polymers and hydrogels, polymeric micelles as delivery carriers for hydrophobic drugs, biodegradable amphiphilic block copolymers, and supramolecular-structured hydrogels using host-guest interactions for biomedical applications.



Dr. Yong Woo Cho is a Principal Scientist at Akina, Inc., where he is involved in research projects on the development of polymeric micellar carriers for poorly soluble drugs and RNA enzyme delivery systems. He has considerable experience in the field of biopharmaceutical formulation development, anti-tumor drug delivery, gene delivery, and tissue engineering. Dr. Cho earned his BS, MS, and PhD in the Department of Chemistry and Polymer Science from Seoul National University, Seoul, Korea. He worked for Korea Institute of Science and Technology as a Post-doctoral research associate where he performed research projects on development of anti-tumor drug delivery systems, regeneration of defected tissues and organs, and development of antibiotics-releasing urethral catheters. Dr. Cho's recent research interests include polymeric self-assembled biomimetic materials, and functional delivery systems to induce endosomal escape for genomics-based pharmaceuticals.



Dr. Kinam Park is the Founder of Akina, Inc., specializing in drug delivery technology. He is also Professor in the Departments of Pharmaceutics and Biomedical Engineering at Purdue University. Dr. Park earned his PhD in Pharmaceutics from the University of Wisconsin in 1983. Following his Post-doctoral training in the Department of Chemical Engineering at the same university, he joined the faculty of Purdue University. Since 1998, he has the joint appointment in the Department of Biomedical Engineering. His current work at Akina is focused on development of controlled-release protein delivery systems using PLGA-PEG block copolymers, diet control aids using biodegradable superporous hydrogels, layer-by-layer coating technology for drug-eluting stents, and novel technology for developing fast-melting tablets.